IVA - Inventiva receives positive recommendation from DMC for late stage trial of NASH treatment
2024-05-17 08:58:37 ET
More on Inventiva
- Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript
- Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
- Inventiva Phase 2 study for MASH drug meets primary endpoint
- Inventiva resumes Phase 3 study for NASH drug, stock up 6%
- Seeking Alpha’s Quant Rating on Inventiva